GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Zhejiang Huakang Pharmaceutical Co Ltd (SHSE:605077) » Definitions » Beneish M-Score

Zhejiang Huakang Pharmaceutical Co (SHSE:605077) Beneish M-Score : -2.38 (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zhejiang Huakang Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.38 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Zhejiang Huakang Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

SHSE:605077' s Beneish M-Score Range Over the Past 10 Years
Min: -2.6   Med: -2   Max: -1.54
Current: -2.38

During the past 8 years, the highest Beneish M-Score of Zhejiang Huakang Pharmaceutical Co was -1.54. The lowest was -2.60. And the median was -2.00.


Zhejiang Huakang Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for Zhejiang Huakang Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Huakang Pharmaceutical Co Beneish M-Score Chart

Zhejiang Huakang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - -2.22 -1.99 -2.00 -2.49

Zhejiang Huakang Pharmaceutical Co Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.93 -2.12 -2.60 -2.49 -2.38

Competitive Comparison of Zhejiang Huakang Pharmaceutical Co's Beneish M-Score

For the Chemicals subindustry, Zhejiang Huakang Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Huakang Pharmaceutical Co's Beneish M-Score Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Zhejiang Huakang Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zhejiang Huakang Pharmaceutical Co's Beneish M-Score falls into.



Zhejiang Huakang Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zhejiang Huakang Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1692+0.528 * 0.9707+0.404 * 0.956+0.892 * 1.1318+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0569+4.679 * -0.008713-0.327 * 1.2879
=-2.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥558 Mil.
Revenue was 634.816 + 740.622 + 673.297 + 718.443 = ¥2,767 Mil.
Gross Profit was 152.464 + 178.964 + 170.415 + 172.551 = ¥674 Mil.
Total Current Assets was ¥3,104 Mil.
Total Assets was ¥6,272 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,215 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥78 Mil.
Total Current Liabilities was ¥855 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2,044 Mil.
Net Income was 79.999 + 96.7 + 89.577 + 95.142 = ¥361 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -151.735 + 196.399 + 166.093 + 205.307 = ¥416 Mil.
Total Receivables was ¥422 Mil.
Revenue was 650.334 + 611.621 + 638.434 + 544.573 = ¥2,445 Mil.
Gross Profit was 150.991 + 148.599 + 158.011 + 120.822 = ¥578 Mil.
Total Current Assets was ¥2,239 Mil.
Total Assets was ¥4,542 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,582 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥65 Mil.
Total Current Liabilities was ¥782 Mil.
Long-Term Debt & Capital Lease Obligation was ¥848 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(557.928 / 2767.178) / (421.607 / 2444.962)
=0.201623 / 0.172439
=1.1692

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(578.423 / 2444.962) / (674.394 / 2767.178)
=0.236578 / 0.243712
=0.9707

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3104.143 + 2215.116) / 6271.911) / (1 - (2238.75 + 1581.583) / 4541.949)
=0.151892 / 0.158878
=0.956

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2767.178 / 2444.962
=1.1318

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1581.583)) / (0 / (0 + 2215.116))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(77.615 / 2767.178) / (64.883 / 2444.962)
=0.028048 / 0.026537
=1.0569

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2043.603 + 855.192) / 6271.911) / ((848.331 + 781.609) / 4541.949)
=0.462187 / 0.358864
=1.2879

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(361.418 - 0 - 416.064) / 6271.911
=-0.008713

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zhejiang Huakang Pharmaceutical Co has a M-score of -2.38 suggests that the company is unlikely to be a manipulator.


Zhejiang Huakang Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Zhejiang Huakang Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Huakang Pharmaceutical Co (SHSE:605077) Business Description

Traded in Other Exchanges
N/A
Address
No. 18, Huagong Road, Huabu Town, Zhejiang Province, Kaihua County, Quzhou, CHN, 324302
Zhejiang Huakang Pharmaceutical Co Ltd is engaged in the research and development, production and sales of various functional sugar alcohols and starch sugar products such as xylitol, sorbitol, maltitol, fructose syrup and others.
Executives
Du Yong Rui Director
Zheng Fang Ming senior management
Jiang Xue Song Supervisors
Yu Jian Ming Directors, senior managers
Chen De Shui Directors, senior managers
Xu Xiao Rong Director
Cheng Xin Ping Directors, senior managers
Yan Xiao Xing Supervisors
Cao Jian Hong Director

Zhejiang Huakang Pharmaceutical Co (SHSE:605077) Headlines

No Headlines